Table 1 Outcomes post haplo-HCT with FD and NFD donors. Matched-pair analysis.

From: The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O009-O172)

 

2 years

180 days

2 years

 

Relapse

NRM

LFS

OS

GRFS

Acute GVHD II-IV

Acute GVHD III-IV

chronic GVHD

ext. chronic GVHD

FD

22.6%[17.8-27.7]

17.7%[13.5-22.3]

59.7%[53.7-65.3]

68.3%[62.5-73.5]

47.8%[41.8-53.6]

29.1%[24-34.4]

9.1%[6.2-12.7]

31%[25.6-36.6]

9.9%[6.6-13.9]

NFD

21.1%[13.9-29.3]

13.2%[7.7-20.2]

65.7%[55.9-73.9]

71.8%[62.3-79.4]

50.9%[41-60]

24%[16.8-31.9]

10.7%[6-17]

38.9%[29.4-48.3]

15.3%[9.1-22.9]

HR (95% CI)

1.04 (0.69-1.58)

0.77 (0.45-1.31)

0.92 (0.66-1.27)

0.9 (0.63-1.28)

0.95 (0.72-1.25)

0.8 (0.52-1.23)

1.28 (0.68-2.4)

1.17 (0.81-1.69)

1.44 (0.82-2.52)

p value

0.84

0.33

0.6

0.56

0.69

0.31

0.44

0.41

0.2

  1. Abbreviations: NRM, non-relapse mortality; LFS, leukemia-free survival; OS, overall survival; GRFS, GVHD-free, relapse-free survival;
Back to article page